These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 23147687)
21. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Falcone C; Emanuele E; D'Angelo A; Buzzi MP; Belvito C; Cuccia M; Geroldi D Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1032-7. PubMed ID: 15731496 [TBL] [Abstract][Full Text] [Related]
22. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Leonardis D; Basta G; Mallamaci F; Cutrupi S; Pizzini P; Tripepi R; Tripepi G; De Caterina R; Zoccali C Nutr Metab Cardiovasc Dis; 2012 Sep; 22(9):748-55. PubMed ID: 21470837 [TBL] [Abstract][Full Text] [Related]
23. Serum high sensitivity C-reactive protein, nitric oxide metabolites, plasma fibrinogen, and lipid parameters in Indian type 2 diabetic males. Sarangi R; Padhi S; Mohapatra S; Swain S; Padhy RK; Mandal MK; Patro SK; Kumar S Diabetes Metab Syndr; 2012; 6(1):9-14. PubMed ID: 23014248 [TBL] [Abstract][Full Text] [Related]
24. Association of uric acid with risk factors for chronic kidney disease and metabolic syndrome in patients with essential hypertension. Seki S; Tsutsui K; Fujii T; Yamazaki K; Anzawa R; Yoshimura M Clin Exp Hypertens; 2010; 32(5):270-7. PubMed ID: 20662727 [TBL] [Abstract][Full Text] [Related]
25. Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in Type 2 diabetic patients. Tsunoda K; Arita M; Yukawa M; Ueyama M; Furuta M; Nakagawa T; Nanjo K; Sanke T J Diabetes Complications; 2005; 19(3):123-7. PubMed ID: 15866055 [TBL] [Abstract][Full Text] [Related]
26. Plasma advanced glycation end products are decreased in obese children compared with lean controls. Sebeková K; Somoza V; Jarcusková M; Heidland A; Podracká L Int J Pediatr Obes; 2009; 4(2):112-8. PubMed ID: 18645732 [TBL] [Abstract][Full Text] [Related]
27. Relationship of fasting total homocysteine, high sensitivity C-reactive protein and features of the metabolic syndrome in Trinidadian subjects. Nayak BS; Pinto Pereira LM; Seemungal T; Davis G; Teelucksingh S; Jagessar A; Legall G Arch Physiol Biochem; 2013 Feb; 119(1):22-6. PubMed ID: 23137347 [TBL] [Abstract][Full Text] [Related]
28. Inflammation but not oxidative stress is associated with beta-chemokine levels and prevalence of cardiovascular disease in uraemic patients. Pawlak K; Pawlak D; Myśliwiec M Cytokine; 2006 Sep; 35(5-6):258-62. PubMed ID: 17070067 [TBL] [Abstract][Full Text] [Related]
29. Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE)--intra- and inter-individual variability in chronic hemodialysis patients. Míková B; Jarolímková E; Benáková H; Dohnal L; Tesař V; Zima T; Kalousová M Scand J Clin Lab Invest; 2012 Jul; 72(4):296-303. PubMed ID: 22384980 [TBL] [Abstract][Full Text] [Related]
30. Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets). Shishido T; Konta T; Nishiyama S; Miyashita T; Miyamoto T; Takasaki S; Nitobe J; Watanabe T; Takeishi Y; Kubota I Clin Exp Hypertens; 2011; 33(2):117-23. PubMed ID: 21269062 [TBL] [Abstract][Full Text] [Related]
35. High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis. Basta G; Castagnini M; Del Turco S; Epistolato MC; Righini P; Sangiorgi GM; De Caterina R; Tanganelli P Eur J Clin Invest; 2009 Dec; 39(12):1065-72. PubMed ID: 19811526 [TBL] [Abstract][Full Text] [Related]
36. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Santos AC; Lopes C; Guimarães JT; Barros H Int J Obes (Lond); 2005 Dec; 29(12):1452-6. PubMed ID: 16077717 [TBL] [Abstract][Full Text] [Related]
37. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709 [TBL] [Abstract][Full Text] [Related]
38. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Aquilante CL; Kosmiski LA; Knutsen SD; Zineh I Metabolism; 2008 Apr; 57(4):494-501. PubMed ID: 18328350 [TBL] [Abstract][Full Text] [Related]
39. Relation of adiponectin and high-sensitivity C-reactive protein to pulse-wave velocity and N-terminal pro-B-type natriuretic peptide in the general population. Sung SH; Chuang SY; Sheu WH; Lee WJ; Chou P; Chen CH Am J Cardiol; 2009 May; 103(10):1411-6. PubMed ID: 19427438 [TBL] [Abstract][Full Text] [Related]
40. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Linnemann B; Voigt W; Nobel W; Janka HU Exp Clin Endocrinol Diabetes; 2006 Mar; 114(3):127-34. PubMed ID: 16636979 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]